TRACKER 6 OCT 2026 · WADA publishes the 2027 Prohibited List, in force January 1, 2027. What changed
plainly graded.

Tirzepatide

Also called "Mounjaro", "Zepbound", "tirz"
FDA approvedWADA: not prohibited
STATUS AS OF
FDA: approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management) · WADA: gLP-1 agonists are not prohibited; WADA says the status is unchanged for 2027 · tracker entry

The short answer: Tirzepatide is an FDA-approved drug from Eli Lilly that acts on two hormone receptors, GIP and GLP-1. As of October 17, 2026 it is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and GLP-1 drugs are not on the 2026 WADA List.

Written by Maren Holt 2 PUBLIC SOURCES · UPDATED 17 OCT 2026 · NO TIES TO SELLERS
How we source

We collect and compare information from public, cited sources. We cannot guarantee that it is complete, current or correct. This is not medical advice. Only a doctor can prescribe, and a doctor should confirm anything you read here before you act on it.

Based on public sources; we cannot guarantee it is correct. Not medical advice. A doctor should prescribe and confirm. Full disclaimer

What is Tirzepatide?

Tirzepatide is a peptide drug that activates the GIP and GLP-1 receptors. It is approved and prescribed under the brand names Mounjaro and Zepbound.

What is Tirzepatide claimed to do, and what does the evidence show?

Overall gradeApproved
Strongest evidencePhase 3 trials
UseClaimedShownGrade
Type 2 diabetes and chronic weight management Lowers blood sugar and body weight Approved by the FDA for these uses on the basis of phase 3 trials. See the label for exactly what was approved.[1] Approved
Type 2 diabetes and chronic weight managementApproved
Claimed: Lowers blood sugar and body weight Shown: Approved by the FDA for these uses on the basis of phase 3 trials. See the label for exactly what was approved.[1]

What are the known risks and side effects of Tirzepatide?

The approved labels list the known side effects and warnings, including a boxed warning. We link to the label rather than restate it.

Who should be especially careful
  • People with a history of eating disorders. Weight-loss drugs can make disordered eating harder to manage. NEDA and 988 can help.
  • People who are pregnant, trying to get pregnant or breastfeeding. There is no human data in pregnancy.
  • Anyone under 18. It has not been studied in young people.
Get medical help now if you have
  • Swelling of the face, lips or throat, trouble breathing, chest pain, a racing heart or fainting. Call 911.
  • Redness spreading from an injection site, warmth, pus or a fever. Get same-day care.
  • Severe stomach pain that won't go away, with or without vomiting. Get same-day care.
  • Unsure what you took or whether a reaction is serious: Poison Control 1-800-222-1222 (free, 24 hours).
  • Thoughts of harming yourself: call or text 988.
If food, weight or exercise feels out of control You are not alone. Talk to someone at the NEDA helpline, or call or text 988.

Is Tirzepatide banned in sport?

GLP-1 agonists are not prohibited; WADA says the status is unchanged for 2027.[2] Anti-doping rules work on strict liability: a positive test counts whatever the label said.

What don't we know about Tirzepatide?

Still unknown
  • How it compares directly with retatrutide: no head-to-head result has been published.
Why this page has no dosing We don't publish doses, schedules or mixing instructions for Tirzepatide or any unapproved peptide. No human dose has been established for most of these uses, so we list what to ask a licensed prescriber instead. Here's why, and who can legally answer

What should you tell your doctor if you're using Tirzepatide?

Tell them exactly what you took, for how long, and where it came from, and bring the label. These questions can help the conversation:

  • Is there an approved treatment for my goal that has been tested in people?
  • What should I watch for, and which symptoms mean I should stop and call you?
  • Could it interact with the medicines I already take?

Compare next

Retatrutide
Sources
  1. DailyMed / US Food and Drug Administration. Mounjaro and Zepbound (tirzepatide) prescribing information .
  2. World Rugby. WADA publishes 2027 Prohibited List (GLP-1 agonists unchanged) , 2026-10-06. (news report)
Changelog
17 OCT 2026 Draft. Statuses read from the regulatory record dated 2026-10-17.
Spotted an error? Report it. We never change a page's updated date without changing its content.